



July 17, 2018

The Honorable Susan Brooks
1030 Longworth House Office Building
Washington, DC 20515

The Honorable Anna Eshoo
241 Cannon House Office Building
Washington, DC 20515

The Honorable Greg Walden
2185 Rayburn House Office Building
Washington, DC 20515

The Honorable Frank Pallone
237 Cannon House Office Building
Washington, DC 20515

Dear Reps. Brooks, Eshoo, Walden, and Pallone:

Thank you to you and your staff for your hard work in introducing H.R. 6378, *the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018*. This legislation, like PAHPRA and PAHPA before it, is vital to ensuring our nation is safe from and prepared for both human-deployed and natural chemical, biological, radiological, and nuclear (CBRN) threats. Emergent is pleased to support PAHPAI.

We are appreciative of your staff for taking the time to meet with us and solicit feedback about the PAHPAI. Thank you for your leadership in ensuring the legislation further strengthens our nation's preparedness for biological threats.

- **Funding Levels:** Emergent strongly supports the robust funding levels authorized in PAHPAI. This funding is needed to continue to grow the public-private partnership Congress created to ensure the US is adequately prepared for CBRN threats. Sustained and expanded investment in these programs is a vital market pull to ensure private partners produce medical countermeasures for the most serious threats we face as a nation, such as anthrax, smallpox, and chemical threats. If the government fails to adequately support the Special Reserve Fund, BARDA, and the SNS, the nation faces the dual risk of squandering resources already invested into research and preparedness, while also being underprepared or unprepared for material threats to our national security.
- **Identified Authorization Funding Levels for Key Programs:** Emergent is strongly supportive of the inclusion of specific funding authorization that breaks out the minimum amounts for the critical Pandemic Influenza and Emerging Infectious Disease (EID) activities supported through BARDA. Specific authorizations help ensure that BARDA's priorities receive consistent funding needed to drive the development of countermeasures to respond to material threats, pandemic influenza, emerging infectious diseases, and other public health hazards.

- **Other Transaction (OT) Authority:** We appreciate your efforts to update the medical countermeasure enterprise's OT authority and harmonize it with the OT authority of other agencies. These changes will provide the enterprise needed flexibility to better prepare for manmade and naturally-occurring biological threats.

The public health threat matrix is real and growing. Reauthorization of PAHPA is vital to ensuring our nation is prepared for the most severe threats facing the country. As introduced, PAHPAI will greatly enhance our nation's biosecurity preparedness. We believe that Emergent is uniquely positioned to enable the U.S. and allied governments to address many of these threats based on our growing portfolio of medical countermeasures, decades of experience and expertise in government partnering and contracting, and our broad and deep manufacturing capabilities. We hope we can be a resource as the committee continues to work towards passage of PAHPAI.

Sincerely,

Chris Frech
Senior Vice President, Global Government Affairs
Emergent BioSolutions, Inc.

###

About Emergent BioSolutions

Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.